Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company focused on developing and commercializing novel, plant-based gastrointestinal products, primarily centered on its FDA-approved drug crofelemer (Mytesi® for HIV-related diarrhea and Canalevia®-CA1 for chemotherapy-induced diarrhea in dogs).
On April 7, 2026, Jaguar Health reported its consolidated financial results for the fourth quarter and full year ended December 31, 2025.
Q4 2025 Financial Highlights:
Full-Year 2025 Financials:
The $16 million upfront cash payment from the Future Pak license agreement (announced in January 2026) is a subsequent event and does not appear in the 2025 financial statements. It provides important non-dilutive capital to support ongoing development of crofelemer for human rare-disease intestinal failure indications.
Nasdaq Listing Update: The company received a noncompliance notice on March 5, 2026, under Nasdaq Listing Rule 5550(a)(2) due to its bid price closing below $1.00 for 30 consecutive business days. Because of prior reverse stock splits, Jaguar is not eligible for a standard compliance period. It requested and received a hearing before the Nasdaq Hearings Panel, scheduled for April 7, 2026. Any delisting action is stayed pending the panel’s final decision. An investor webcast is planned for April 10, 2026, at 8:30 a.m. ET to discuss the results and updates.
Despite ongoing operating losses and a challenging balance sheet, Jaguar Health continues to focus on advancing its crofelemer pipeline while leveraging licensing deals for non-dilutive funding.
